Can State Bank of India Maintain Its Profit Momentum After a Strong Q2?
About State Bank of India
PL Capital has reiterated a Buy rating on State Bank of India (SBI) with a revised target price of ₹1,000. The bank posted a robust quarter, driven by higher net interest income, stable margins, and controlled asset quality indicators. Core profitability remains strong despite rising operating costs.
Key Financial Highlights (Q2 FY25)
| Metric | Q2 FY25 | YoY Change |
|---|---|---|
| Net Profit | ₹14,160 Cr | +11.9% |
| NII Growth | +13% | Driven by CASA and fee income |
| Loan Growth | 3.9% QoQ | Steady corporate disbursements |
| Gross NPA Ratio | 2.6% | Improved from 2.7% |
| LCR | 143% | Healthy liquidity position |
Net Profit ₹14,160 Cr — up nearly 12% YoY, aided by higher fees and stable interest margins.
NII Growth 13% — supported by deposit expansion and CASA growth.
Asset Quality — remains resilient with net slippage of just 9bps QoQ.
Investors tracking large-cap banking performance can explore the Nifty Tip for related sector opportunities.
Strengths & Weaknesses
- ✅ Largest PSU bank with diversified income streams.
- ✅ Improving margin profile with CASA-led deposit growth.
- ⚠️ Higher operating expenses due to wage revisions.
- ⚠️ Slow loan growth in retail segments.
Opportunities
- 💡 Rising credit demand in retail and SME lending.
- 💡 Ongoing tech investments may improve cost efficiency.
- 💡 Lower provisioning supports sustained profitability.
Threats
- 📉 Margin compression from rising deposit competition.
- 📉 Potential impact of global rate volatility on bond yields.
- 📉 Political pressures in PSU space may affect reform pace.
Valuation & Investment View
- Short-term: Supported by strong earnings visibility.
- Medium-term: Improving ROE with better fee income outlook.
- Long-term: Potential re-rating as asset quality cycle stabilizes.
For sectoral positioning insights, refer to BankNifty Positional Tip.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, notes that SBI’s strong fundamentals and improving fee income make it a steady compounder within PSU banking. Explore more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
Will Sun Pharma Maintain Its Growth Momentum Through FY26?
About Sun Pharma
Sun Pharmaceutical Industries reported a solid Q2 FY25 with healthy margins and robust global sales. The company’s specialty business continued to gain share in the US and EU, while India growth held in double digits. InCred Equities maintained its Add call with a target of ₹2,000.
Financial Summary (Q2 FY25)
| Metric | Q2 FY25 | YoY |
|---|---|---|
| Revenue Growth | +2% | Stable performance |
| EBITDA Margin | 28.3% | +30bps YoY |
| R&D Spending | 5.4% of revenue | Focus on specialty drugs |
| US Business Growth | +5% QoQ | Driven by specialty portfolio |
| EU Market Share | 60% | Steady in dermatology |
Margins 28.3% — aligned with Bloomberg estimates, supported by cost discipline and specialty focus.
R&D Spend 5.4% — reflects consistent innovation investments for long-term pipeline strength.
Readers tracking healthcare and pharma trends can follow Nifty Positional Tip for sectoral trend cues.
Opportunities
- 💡 Expanding US specialty drug portfolio.
- 💡 New product launches in chronic therapies.
- 💡 Global presence across 100+ countries enables scale advantage.
Threats
- 📉 Regulatory risks in the US market.
- 📉 Currency fluctuations may impact profitability.
- 📉 Competitive pricing pressure in generics.
Valuation & Investment View
- Short-term: Supported by strong US performance and margin stability.
- Medium-term: Specialty focus to drive double-digit earnings.
- Long-term: Strong balance sheet and R&D-led growth visibility.
For trading cues in large-cap pharma space, refer to BankNifty Positional Tip.
Investor Takeaway
According to Gulshan Khera, CFP®, Sun Pharma remains a solid long-term compounder with sustainable growth in specialty and branded markets. Explore more expert insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
